Add to ORKGThis presentation addresses the question of how patent settlements should be treated under EU competition law. This is a highly controversial subject and there are currently several cases pending before the EU courts dealing with this issue. This presentation critiques the approach taken by the European Commission and offers an approach that balances the competing interests at stake
The overwhelming majority of intellectual property lawsuits settle before trial. These settlements i...
In the pharmaceutical sector, firms often build patent portfolios in order to better protect their i...
The aim of the paper is to analyse the issue of reverse payment agreements concluded in a context of...
This webinar addressed the question of how patent settlements should be treated under EU competition...
This thesis focuses on so-called “reverse payment patent settlements” or “pay-for-delay settlements”...
Within the tool-box developed by originator companies in order to prepare and respond to generic en...
Patent settlements in which the patentee pays the alleged infringer to stay out of the market are la...
Although brand-name pharmaceutical companies routinely procure patents on their innovative medicatio...
In its Pharmaceutical Sector Inquiry Report of 2009, the European Commission identified ‘defensive p...
Several federal courts of appeal have recently ruled on the issue of whether a pharmaceutical patent...
This presentation discusses recent developments in EU competition law in the pharmaceutical industry...
This presentation offers a critical appraisal of the EU General Court’s judgment in the Lundbeck cas...
The pharmaceutical market is a billon euro industry and the competition on the market is highly inte...
The aim of the paper is to analyse the issue of reverse payment agreements concluded in a context of...
Pay for delay deals are agreements between a brand-name drug manufacturer and a potential generic co...
The overwhelming majority of intellectual property lawsuits settle before trial. These settlements i...
In the pharmaceutical sector, firms often build patent portfolios in order to better protect their i...
The aim of the paper is to analyse the issue of reverse payment agreements concluded in a context of...
This webinar addressed the question of how patent settlements should be treated under EU competition...
This thesis focuses on so-called “reverse payment patent settlements” or “pay-for-delay settlements”...
Within the tool-box developed by originator companies in order to prepare and respond to generic en...
Patent settlements in which the patentee pays the alleged infringer to stay out of the market are la...
Although brand-name pharmaceutical companies routinely procure patents on their innovative medicatio...
In its Pharmaceutical Sector Inquiry Report of 2009, the European Commission identified ‘defensive p...
Several federal courts of appeal have recently ruled on the issue of whether a pharmaceutical patent...
This presentation discusses recent developments in EU competition law in the pharmaceutical industry...
This presentation offers a critical appraisal of the EU General Court’s judgment in the Lundbeck cas...
The pharmaceutical market is a billon euro industry and the competition on the market is highly inte...
The aim of the paper is to analyse the issue of reverse payment agreements concluded in a context of...
Pay for delay deals are agreements between a brand-name drug manufacturer and a potential generic co...
The overwhelming majority of intellectual property lawsuits settle before trial. These settlements i...
In the pharmaceutical sector, firms often build patent portfolios in order to better protect their i...
The aim of the paper is to analyse the issue of reverse payment agreements concluded in a context of...